Literature DB >> 23507558

MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer.

Sung-Min Kang1, Heon-Jin Lee, Je-Yoel Cho.   

Abstract

MicroRNAs constitute a class of small noncoding RNAs that play roles in tumorigenesis. We found that NKX2-1 protein levels were generally high in the lung cancer tissues whereas miRNA-365 expression levels were downregulated. Ectopic miR-365 expression decreased NKX2-1 expression in lung cancer cell lines. Transfection of a miR-365 mimic led to reduced proliferation of lung cancer cells; conversely, a miR-365 inhibitor slightly increased cell proliferation. The NKX2-1 overexpression significantly increased the cell proliferation by overcoming the suppressive effect of miR-365. Our data suggest that miR-365 is an important regulator of NKX2-1 and can be a target for lung cancer therapies.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23507558     DOI: 10.1016/j.canlet.2013.03.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

1.  Associations of deregulation of mir-365 and its target mRNA TTF-1 and survival in patients with NSCLC.

Authors:  Ruifang Sun; Zhigang Liu; Gang Ma; Weidong Lv; Xinliang Zhao; Guangyan Lei; Changfu Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Prognostic significance and anti-proliferation effect of microRNA-365 in hepatocellular carcinoma.

Authors:  Zhizhao Chen; Zufa Huang; Qifa Ye; Yingzi Ming; Sheng Zhang; Yujun Zhao; Lian Liu; Qiang Wang; Ke Cheng
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells.

Authors:  F Akbari Moqadam; J M Boer; E A M Lange-Turenhout; R Pieters; M L den Boer
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

4.  Peptide regulation of gene expression and protein synthesis in bronchial epithelium.

Authors:  V Kh Khavinson; S M Tendler; B F Vanyushin; N A Kasyanenko; I M Kvetnoy; N S Linkova; V V Ashapkin; V O Polyakova; V S Basharina; A Bernadotte
Journal:  Lung       Date:  2014-07-12       Impact factor: 2.584

Review 5.  The complexity of thyroid transcription factor 1 with both pro- and anti-oncogenic activities.

Authors:  David Mu
Journal:  J Biol Chem       Date:  2013-07-01       Impact factor: 5.157

6.  Roles of Mir-144-ZFX pathway in growth regulation of non-small-cell lung cancer.

Authors:  Wangjian Zha; Liu Cao; Ying Shen; Mao Huang
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

Review 7.  Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy.

Authors:  Marko Jakopovic; Anish Thomas; Sanjeeve Balasubramaniam; David Schrump; Giuseppe Giaccone; Susan E Bates
Journal:  Front Oncol       Date:  2013-10-09       Impact factor: 6.244

8.  Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.

Authors:  Zheng Wang; Zhaoshi Bao; Wei Yan; Gan You; Yinyan Wang; Xuejun Li; Wei Zhang
Journal:  J Exp Clin Cancer Res       Date:  2013-08-29

9.  MicroRNA-365 inhibits vascular smooth muscle cell proliferation through targeting cyclin D1.

Authors:  Peng Zhang; Cuiying Zheng; Hui Ye; Yan Teng; Bin Zheng; Xiao Yang; Jishuai Zhang
Journal:  Int J Med Sci       Date:  2014-05-21       Impact factor: 3.738

10.  miR-365 promotes cutaneous squamous cell carcinoma (CSCC) through targeting nuclear factor I/B (NFIB).

Authors:  Meijuan Zhou; Liang Zhou; Li Zheng; Ling Guo; Yinghui Wang; Hongxia Liu; Chengshan Ou; Zhenhua Ding
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.